C. Smolenschi

An ongoing open-label, phase 2 trial of RP2 Or RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma

BackgroundColorectal cancer (CRC) is the third most frequently diagnosed cancer and the second leading cause of cancer-related mortality worldwide. PD-1/PD-L1 inhibition, in combination w...

Elena Elez Sr., MD, PhD;

C. Smolenschi ;

Dale Shepard ;

Tanios Bekaii-Saab , MD, FACP;

Jaroslaw Jac ;

06/25/2023

Impact of molecular profiling on survival in patients with advanced biliary tract cancers

Biliary tract cancers (BTC) are a group of rare cancers (intrahepatic cholangiocarcinoma [ICC], extrahepatic cholangiocarcinoma [ECC], and gallbladder carcinoma [GBC]) that are epidemiolo...

P. Dartigues ;

M. Bani ;

C. Smolenschi ;

J. Scoazec ;

Michel P. Ducreux , MD, PhD;

D. Malka ;

L. Antoun ;

I. Deneche ;

A. Boileve ;

A. Tarabay ;

E. Rouleau ;

A. Hollebecque ;